Last $1.58 USD
Change Today -0.12 / -7.06%
Volume 165.8K
As of 5:20 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

anthera pharmaceuticals inc (ANTH) Snapshot

Open
$1.69
Previous Close
$1.70
Day High
$1.72
Day Low
$1.58
52 Week High
03/13/14 - $3.79
52 Week Low
09/19/14 - $1.53
Market Cap
36.2M
Average Volume 10 Days
197.0K
EPS TTM
$-1.52
Shares Outstanding
22.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANTHERA PHARMACEUTICALS INC (ANTH)

anthera pharmaceuticals inc (ANTH) Related Bloomberg News

View More Bloomberg News

anthera pharmaceuticals inc (ANTH) Related Businessweek News

No Related Businessweek News Found

anthera pharmaceuticals inc (ANTH) Details

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation and autoimmune diseases. It is developing blisibimod, a Phase III product candidate that targets elevated levels of B-cell activating factor associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus, IgA nephropathy, lupus nephritis, multiple myeloma, vasculitis, idiopathic thrombocytopenia purpura, and others. The company was founded in 2004 and is headquartered in Hayward, California.

25 Employees
Last Reported Date: 03/28/14
Founded in 2004

anthera pharmaceuticals inc (ANTH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $577.3K
Senior Vice President of Finance & Administra...
Total Annual Compensation: $224.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $350.0K
Chief Technology Officer and Senior Vice Pres...
Total Annual Compensation: $340.0K
Compensation as of Fiscal Year 2013.

anthera pharmaceuticals inc (ANTH) Key Developments

Anthera Pharmaceuticals, Inc. - Special Call

To discuss an exclusive license agreement for the development and commercialization of subcutaneous blisibimod in Japan and potentially other countries throughout Asia

Anthera Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:30 PM

Anthera Pharmaceuticals, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 04:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Paul F. Truex, Chief Executive Officer, President and Director.

Anthera Pharmaceuticals Receives Non-Compliance Notice From NASDAQ

On November 18, 2014, Anthera Pharmaceuticals, Inc. received a letter from The Nasdaq Stock Market informing the Company that its most recent Form 10-Q for the period ended September 30, 2014 reported stockholders’ equity fell below the minimum of $10,000,000 for continued inclusion under Listing Rule 5450(b)(1)(A). The letter stated that the Company may submit a plan to regain compliance to Nasdaq within 45 days of receipt of the letter. The Company intends to do so. If the plan is accepted, Nasdaq can grant an extension of up to 180 days for the Company to regain compliance. The letter has no immediate effect on the listing of the Company's common stock.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANTH:US $1.58 USD -0.12

ANTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANTH.
View Industry Companies
 

Industry Analysis

ANTH

Industry Average

Valuation ANTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTHERA PHARMACEUTICALS INC, please visit www.anthera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.